Ardelyx Inc (ARDX)

$5.04 -0.02 (-0.40%)
Market Cap 1.22B
Revenue (ttm) 333.62M
Net Income (ttm) -39.14M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -11.73%
Debt to Equity Ratio 1.44
Volume 2,289,000
Avg Vol 3,277,604
Day's Range N/A - N/A
Shares Out 240.98M
Stochastic %K 40%
Beta 0.67
Analysts Strong Sell
Price Target $11.36

Company Profile

Ardelyx, Inc. discovers, develops, and commercializes medicines to treat unmet medical needs in the United States and internationally. The company offers IBSRELA, a minimally absorbed small molecule therapy for the treatment of patients with irritable bowel syndrome with constipation; and XPHOZAH, a phosphate absorption inhibitor to reduce serum phosphorus in adults with chronic kidney disease on dialysis. The company was formerly known as Nteryx, Inc. and changed its name to Ardelyx, Inc. in Ju...

Industry: Biotechnology
Sector: Healthcare
Phone: 510 745 1700
Address:
400 Fifth Avenue, Suite 210, Waltham, United States
GladysFoster
GladysFoster Oct. 25 at 4:13 PM
$ARDX obviously this will probably knock us down further with losses (due to SP drop) than we will probably receive (if they win) but are there many of you who bought much more within the October 31, 2023 – July 1, 2024 timeframe set by the class action?
1 · Reply
donkeykongreturns
donkeykongreturns Oct. 25 at 2:22 PM
$ARDX All the ingrediants of a setup. 1. Possible rate cut wednesday 2. Trump <> Xi meet thursday 3. ARDX er thursday after hours. Scripts were solid across the quarter. ---> Friday should be interesting 4. Price is at the Last Point of Supply (LPS), dwindling volume and balance price on a 7 year timeline with 19 million shares short 5. New CFO starts next week 6. Kidney week starts the day after the new CFO starts 7. Q4 is likely profitable 8. Appeal news is likely months out 9. 95% of the FTC and SEC are furloughed 10. M&A kicked up over the last few weeks with AVDL and some other small companies being acquired 11. This stock loves November.
2 · Reply
ToadTrader
ToadTrader Oct. 25 at 3:31 AM
$ARDX It's even more amazing that we ended the day / week, right there on a fine line, between $5.04 and $5.05...ARE we talking of a "Fair Market Value", or what? Only 4-more trading days, until someone spills the beans! Have a safe, weekend, we need everyone paying attention in the coming week! CHEERS
1 · Reply
Michael_Milking
Michael_Milking Oct. 24 at 10:30 PM
$ARDX Amazing how retail is buying what non-retails dumps. Raab continues to hire more and more and more and more management in hopes of replacing S. Rodriguez IQ. EPS a miss quite likely due to extreme spending. Mr. Raab will likely give guidance, but its more likely to be DEI & aimed at those who identify with the Left crowd. This company took shareholders & had them miss a RECORD $XBI run. Cult leaders here will tell you management knows what they are doing. Raab makes millions either way. Vote today to tell Raab to join CMS. Capital raise and dilution are Raab’s fav words according to outstanding shares.
1 · Reply
ChandlerBing74
ChandlerBing74 Oct. 24 at 9:57 PM
$ARDX there were no run up previous quarter. Numbers did the runup.
0 · Reply
Cameohitch
Cameohitch Oct. 24 at 8:30 PM
$ARDX "#2340 Tenapanor administration combined with phosphate binders provides synergistic phosphate lowering effect." published by the Oxford University Press 3 days ago. "Conclusion: Oral administration of tenapanor significantly reduced P adsorption and improved serum P level in patients undergoing HD either when it was administrated alone or adding on P binders. This P absorption reduction effect of tenapanor was greatly enhanced when it was added on P binders. The mechanism of this synergistic effect would be an important research question." https://academic.oup.com/ndt/article/40/Supplement_3/gfaf116.0676/8295150
0 · Reply
FerreroRocher
FerreroRocher Oct. 24 at 8:00 PM
$ARDX Is it Monday yet?
1 · Reply
GladysFoster
GladysFoster Oct. 24 at 7:30 PM
$ARDX the fatigue is real.
1 · Reply
SNOB_ORDER
SNOB_ORDER Oct. 24 at 6:59 PM
$ARDX Short Interest -370 K to 19,111,230 from 19,480,138
1 · Reply
Diddysjury
Diddysjury Oct. 24 at 6:52 PM
$ARDX
0 · Reply
Latest News on ARDX
Ardelyx Announces Four Abstracts Accepted for Poster Presentations at the American Society of Nephrology's Kidney Week

Oct 21, 2025, 8:00 AM EDT - 4 days ago

Ardelyx Announces Four Abstracts Accepted for Poster Presentations at the American Society of Nephrology's Kidney Week

Ardelyx to Report Third Quarter 2025 Financial Results on October 30, 2025

Oct 13, 2025, 8:35 AM EDT - 12 days ago

Ardelyx to Report Third Quarter 2025 Financial Results on October 30, 2025

Ardelyx Appoints Experienced Finance Executive, Sue Hohenleitner, as Chief Financial Officer

Oct 13, 2025, 8:30 AM EDT - 12 days ago

Ardelyx Appoints Experienced Finance Executive, Sue Hohenleitner, as Chief Financial Officer

Ardelyx, Inc. (ARDX) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference Transcript

Sep 8, 2025, 10:11 AM EDT - 6 weeks ago

Ardelyx, Inc. (ARDX) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference Transcript

Ardelyx, Inc. (ARDX) Presents At Citi's Biopharma Back To School Conference Transcript

Sep 3, 2025, 4:42 PM EDT - 7 weeks ago

Ardelyx, Inc. (ARDX) Presents At Citi's Biopharma Back To School Conference Transcript

Ardelyx to Participate in Upcoming Investor Conferences

Aug 25, 2025, 8:00 AM EDT - 2 months ago

Ardelyx to Participate in Upcoming Investor Conferences

Ardelyx: Improved Outlook For Ibsrela And Xphozah

Aug 15, 2025, 6:17 AM EDT - 2 months ago

Ardelyx: Improved Outlook For Ibsrela And Xphozah

Ardelyx, Inc. (ARDX) Q2 2025 Earnings Call Transcript

Aug 4, 2025, 8:11 PM EDT - 2 months ago

Ardelyx, Inc. (ARDX) Q2 2025 Earnings Call Transcript

Ardelyx Announces Changes to the Executive Leadership Team

Aug 4, 2025, 4:08 PM EDT - 2 months ago

Ardelyx Announces Changes to the Executive Leadership Team

Ardelyx Reports Second Quarter 2025 Financial Results and Provides Business Update

Aug 4, 2025, 4:01 PM EDT - 2 months ago

Ardelyx Reports Second Quarter 2025 Financial Results and Provides Business Update

Ardelyx to Report Second Quarter 2025 Financial Results on August 4, 2025

Jul 21, 2025, 8:00 AM EDT - 3 months ago

Ardelyx to Report Second Quarter 2025 Financial Results on August 4, 2025

Ardelyx Appoints Mike Kelliher Chief Business Officer and James P. Brady Chief Human Resources Officer

Jun 2, 2025, 4:05 PM EDT - 5 months ago

Ardelyx Appoints Mike Kelliher Chief Business Officer and James P. Brady Chief Human Resources Officer

Ardelyx to Participate at the Jefferies Global Healthcare Conference 2025

May 21, 2025, 8:00 AM EDT - 5 months ago

Ardelyx to Participate at the Jefferies Global Healthcare Conference 2025

Ardelyx Presents Data Supporting IBSRELA® (tenapanor) at Digestive Disease Week 2025 Conference

May 6, 2025, 8:01 AM EDT - 6 months ago

Ardelyx Presents Data Supporting IBSRELA® (tenapanor) at Digestive Disease Week 2025 Conference

Ardelyx: Revenue Misses And Losses Widen Amid XPHOZAH Uncertainty

May 2, 2025, 10:07 AM EDT - 6 months ago

Ardelyx: Revenue Misses And Losses Widen Amid XPHOZAH Uncertainty

Ardelyx, Inc. (ARDX) Q1 2025 Earnings Call Transcript

May 1, 2025, 10:06 PM EDT - 6 months ago

Ardelyx, Inc. (ARDX) Q1 2025 Earnings Call Transcript

Ardelyx Reports First Quarter 2025 Financial Results and Provides Business Update

May 1, 2025, 4:01 PM EDT - 6 months ago

Ardelyx Reports First Quarter 2025 Financial Results and Provides Business Update

Ardelyx Appoints Merdad Parsey, M.D., Ph.D. to its Board of Directors

Apr 29, 2025, 8:00 AM EDT - 6 months ago

Ardelyx Appoints Merdad Parsey, M.D., Ph.D. to its Board of Directors

Ardelyx Announces Three Abstracts Accepted for Poster Presentations at Digestive Disease Week 2025 Conference

Apr 24, 2025, 8:01 AM EDT - 6 months ago

Ardelyx Announces Three Abstracts Accepted for Poster Presentations at Digestive Disease Week 2025 Conference

Ardelyx to Report First Quarter 2025 Financial Results on May 1, 2025

Apr 17, 2025, 8:00 AM EDT - 6 months ago

Ardelyx to Report First Quarter 2025 Financial Results on May 1, 2025

Post-Hoc Analysis of the OPTIMIZE Study Supporting XPHOZAH® (tenapanor) to be Presented at the National Kidney Foundation Spring Clinical Meetings

Apr 10, 2025, 4:02 PM EDT - 7 months ago

Post-Hoc Analysis of the OPTIMIZE Study Supporting XPHOZAH® (tenapanor) to be Presented at the National Kidney Foundation Spring Clinical Meetings

Ardelyx to Share a Post-Hoc Analysis of the OPTIMIZE Study Supporting XPHOZAH® (tenapanor) at the National Kidney Foundation Spring Clinical Meetings

Mar 31, 2025, 4:03 PM EDT - 7 months ago

Ardelyx to Share a Post-Hoc Analysis of the OPTIMIZE Study Supporting XPHOZAH® (tenapanor) at the National Kidney Foundation Spring Clinical Meetings

Ardelyx Announces the First Recipients of Derek Forfang Patient Advocate Award

Mar 13, 2025, 8:02 AM EDT - 8 months ago

Ardelyx Announces the First Recipients of Derek Forfang Patient Advocate Award

Undercovered Dozen: Ardelyx, Aviva, Nutrien, Heartland Express +

Mar 1, 2025, 8:30 AM EST - 8 months ago

Undercovered Dozen: Ardelyx, Aviva, Nutrien, Heartland Express +

HTLD NTR

Tenapanor Approved in China for Hyperphosphatemia

Feb 26, 2025, 7:00 AM EST - 8 months ago

Tenapanor Approved in China for Hyperphosphatemia

Ardelyx: Limited Pipeline, Rising Costs, And Uncertain Growth Ahead (Downgrade)

Feb 24, 2025, 2:28 PM EST - 8 months ago

Ardelyx: Limited Pipeline, Rising Costs, And Uncertain Growth Ahead (Downgrade)

3 Biotech/Healthcare Names Under $10 I Am Buying Now

Feb 21, 2025, 4:21 PM EST - 8 months ago

3 Biotech/Healthcare Names Under $10 I Am Buying Now

GERN MRNA PSNL TEM

Ardelyx, Inc. (ARDX) Q4 2024 Earnings Call Transcript

Feb 20, 2025, 2:32 PM EST - 8 months ago

Ardelyx, Inc. (ARDX) Q4 2024 Earnings Call Transcript

Ardelyx Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update

Feb 20, 2025, 7:30 AM EST - 8 months ago

Ardelyx Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update

Ardelyx to Present at the TD Cowen 45th Annual Health Care Conference

Feb 19, 2025, 8:01 AM EST - 8 months ago

Ardelyx to Present at the TD Cowen 45th Annual Health Care Conference

Ardelyx to Report Full Year and Fourth Quarter 2024 Financial Results on February 20, 2025

Jan 30, 2025, 4:30 PM EST - 9 months ago

Ardelyx to Report Full Year and Fourth Quarter 2024 Financial Results on February 20, 2025

Ardelyx Provides Update on Increasing Commercial Momentum and 2025 Strategic Priorities

Jan 13, 2025, 8:03 AM EST - 10 months ago

Ardelyx Provides Update on Increasing Commercial Momentum and 2025 Strategic Priorities

Ardelyx to Present at the 43rd Annual J.P. Morgan Healthcare Conference

Jan 6, 2025, 8:00 AM EST - 10 months ago

Ardelyx to Present at the 43rd Annual J.P. Morgan Healthcare Conference

Ardelyx Lost The Lawsuit, But The Kidney PATIENT Act Will Save It

Nov 24, 2024, 6:36 AM EST - 11 months ago

Ardelyx Lost The Lawsuit, But The Kidney PATIENT Act Will Save It

Ardelyx to Participate at the Piper Sandler 36th Annual Healthcare Conference

Nov 20, 2024, 8:00 AM EST - 1 year ago

Ardelyx to Participate at the Piper Sandler 36th Annual Healthcare Conference

Ardelyx's Medicare Setback Casts Doubt On Long-Term Viability

Nov 14, 2024, 9:34 AM EST - 1 year ago

Ardelyx's Medicare Setback Casts Doubt On Long-Term Viability

Ardelyx Responds to District Court Decision Granting Motion to Dismiss

Nov 8, 2024, 12:31 PM EST - 1 year ago

Ardelyx Responds to District Court Decision Granting Motion to Dismiss

Ardelyx to Participate at the 2024 Jefferies London Healthcare Conference

Nov 5, 2024, 8:00 AM EST - 1 year ago

Ardelyx to Participate at the 2024 Jefferies London Healthcare Conference

Ardelyx, Inc. (ARDX) Q3 2024 Earnings Call Transcript

Oct 31, 2024, 11:20 PM EDT - 1 year ago

Ardelyx, Inc. (ARDX) Q3 2024 Earnings Call Transcript

Ardelyx Reports Third Quarter 2024 Financial Results and Provides Business Update

Oct 31, 2024, 4:02 PM EDT - 1 year ago

Ardelyx Reports Third Quarter 2024 Financial Results and Provides Business Update

GladysFoster
GladysFoster Oct. 25 at 4:13 PM
$ARDX obviously this will probably knock us down further with losses (due to SP drop) than we will probably receive (if they win) but are there many of you who bought much more within the October 31, 2023 – July 1, 2024 timeframe set by the class action?
1 · Reply
donkeykongreturns
donkeykongreturns Oct. 25 at 2:22 PM
$ARDX All the ingrediants of a setup. 1. Possible rate cut wednesday 2. Trump <> Xi meet thursday 3. ARDX er thursday after hours. Scripts were solid across the quarter. ---> Friday should be interesting 4. Price is at the Last Point of Supply (LPS), dwindling volume and balance price on a 7 year timeline with 19 million shares short 5. New CFO starts next week 6. Kidney week starts the day after the new CFO starts 7. Q4 is likely profitable 8. Appeal news is likely months out 9. 95% of the FTC and SEC are furloughed 10. M&A kicked up over the last few weeks with AVDL and some other small companies being acquired 11. This stock loves November.
2 · Reply
ToadTrader
ToadTrader Oct. 25 at 3:31 AM
$ARDX It's even more amazing that we ended the day / week, right there on a fine line, between $5.04 and $5.05...ARE we talking of a "Fair Market Value", or what? Only 4-more trading days, until someone spills the beans! Have a safe, weekend, we need everyone paying attention in the coming week! CHEERS
1 · Reply
Michael_Milking
Michael_Milking Oct. 24 at 10:30 PM
$ARDX Amazing how retail is buying what non-retails dumps. Raab continues to hire more and more and more and more management in hopes of replacing S. Rodriguez IQ. EPS a miss quite likely due to extreme spending. Mr. Raab will likely give guidance, but its more likely to be DEI & aimed at those who identify with the Left crowd. This company took shareholders & had them miss a RECORD $XBI run. Cult leaders here will tell you management knows what they are doing. Raab makes millions either way. Vote today to tell Raab to join CMS. Capital raise and dilution are Raab’s fav words according to outstanding shares.
1 · Reply
ChandlerBing74
ChandlerBing74 Oct. 24 at 9:57 PM
$ARDX there were no run up previous quarter. Numbers did the runup.
0 · Reply
Cameohitch
Cameohitch Oct. 24 at 8:30 PM
$ARDX "#2340 Tenapanor administration combined with phosphate binders provides synergistic phosphate lowering effect." published by the Oxford University Press 3 days ago. "Conclusion: Oral administration of tenapanor significantly reduced P adsorption and improved serum P level in patients undergoing HD either when it was administrated alone or adding on P binders. This P absorption reduction effect of tenapanor was greatly enhanced when it was added on P binders. The mechanism of this synergistic effect would be an important research question." https://academic.oup.com/ndt/article/40/Supplement_3/gfaf116.0676/8295150
0 · Reply
FerreroRocher
FerreroRocher Oct. 24 at 8:00 PM
$ARDX Is it Monday yet?
1 · Reply
GladysFoster
GladysFoster Oct. 24 at 7:30 PM
$ARDX the fatigue is real.
1 · Reply
SNOB_ORDER
SNOB_ORDER Oct. 24 at 6:59 PM
$ARDX Short Interest -370 K to 19,111,230 from 19,480,138
1 · Reply
Diddysjury
Diddysjury Oct. 24 at 6:52 PM
$ARDX
0 · Reply
ToadTrader
ToadTrader Oct. 24 at 6:39 PM
$ARDX
0 · Reply
puncho88
puncho88 Oct. 24 at 6:31 PM
$ARDX one day...
2 · Reply
zeromnil
zeromnil Oct. 24 at 5:28 PM
$ARDX Fortunately I have been in ardx so long my average is still well below five, but this is truly the red-headed step-child of my portfolio.
0 · Reply
Bio_Invest101
Bio_Invest101 Oct. 24 at 5:10 PM
$ARDX The overall market even biotech sector has gone up huge lately but ARDX has been chokedhold at $5 not because of potential bad 3rd Q ER which I think it will be good . IMO It’s most likely the potential deal that the 2-Mike are working behind the doors got leaked from many part of deal participants. As usual the acquiring company SP get depressed especially we only have about $200 M cash.
2 · Reply
WestTexasTycoon
WestTexasTycoon Oct. 24 at 5:04 PM
$ARDX
0 · Reply
TonySoprano1987
TonySoprano1987 Oct. 24 at 4:58 PM
$ARDX winning ?!
2 · Reply
Bangra
Bangra Oct. 24 at 3:27 PM
$ARDX
0 · Reply
BillionerOfKing
BillionerOfKing Oct. 24 at 2:59 PM
$ARDX Current Stock Price: $5.03 Contracts to trade: $5 ARDX Nov 21 2025 Call Entry: $0.45 Exit: $0.89 ROI: 97% Hold ~30 days Shared as daily free alerts and for educational purposes only. https://dailypickai.com/freealerts
0 · Reply
MedHS55
MedHS55 Oct. 24 at 2:43 PM
$ARDX 25k block at $5.02
0 · Reply
bernardbaruch
bernardbaruch Oct. 24 at 2:29 PM
$ARDX Big seller, takes a long time lol. They keep pretending they are “done”. Algos, MMs have them by the gonads.
2 · Reply
donkeykongreturns
donkeykongreturns Oct. 24 at 2:26 PM
$ARDX Almost has to retest the lower VWAP ($4.97), but they aren't leaving a share untested before this ER. Watch for the big wick before the ER.
0 · Reply
Tomasini
Tomasini Oct. 24 at 2:16 PM
$ARDX shorts own this stock
2 · Reply